179811-83-7

Basic information

• Product Name: methyl 2-amino[4-(trifluoromethoxy)phenyl]acetate hydrochloride
• Synonyms: methyl 2-amino[4-(trifluoromethoxy)phenyl]acetate hydrochloride
• CAS NO: 179811-83-7
• Molecular Weight: 285.65
• Mol File: 179811-83-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 2-amino[4-(trifluoromethoxy)phenyl]acetate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-amino[4-(trifluoromethoxy)phenyl]acetate hydrochloride(179811-83-7)
• EPA Substance Registry System: methyl 2-amino[4-(trifluoromethoxy)phenyl]acetate hydrochloride(179811-83-7)

Safety Data

• Hazardous Substances Data: 179811-83-7(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 261952-24-3 2-amino-2-(4-(trifluoromethoxy)phenyl)acetic acid 

Downstream Products

• 950651-14-6 ethyl (2-oxo-3-{4-[(trifluoromethyl)oxy]phenyl}-1,4-diazaspiro[4.5]dec-3-en-1-yl)acetate 
• 950651-16-8 (2-oxo-3-{4-[(trifluoromethyl)oxy]phenyl}-1,4-diazaspiro[4.5]dec-3-en-1-yl)acetyl chloride 
• 950651-15-7 (2-oxo-3-{4-[(trifluoromethyl)oxy]phenyl}-1,4-diazaspiro[4.5]dec-3-en-1-yl)acetic acid 
• 950651-11-3 2-amino-2-(4-(trifluoromethoxy)phenyl)acetamide 

Relevant articles and documents

NOVEL BIARYL AMIDE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a compound having PDE2A selective inhibitory action, and a pharmaceutical composition comprising the same. SOLUTION: This invention relates to compounds represented by general formula (I) [where p is an integer of 0-6; q is an integer of 1-5; X1 is C-H, N, or O; X2 is N or N-R4b; X3 is N-R4a, C-R4b, or C-H; ring A is a monocyclic heteroaryl ring and the like; ring Q is a benzene ring and the like; R1, R2a, R2b, and R3 are an alkyl group and the like] or their pharmaceutically acceptable salts, or their solvates, and pharmaceutical compositions comprising them. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF

Compounds of formula (I) and salts and solvates thereof are provided: wherein R1 to R8 and n are defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.